Zobrazeno 1 - 10
of 139
pro vyhledávání: '"Catherine Pellat‐Deceunynck"'
Autor:
Romane Durand, Céline Bellanger, Géraldine Descamps, Christelle Dousset, Sophie Maïga, Jennifer Derrien, Laura Thirouard, Louise Bouard, Hélène Asnagli, Philip Beer, Andrew Parker, Patricia Gomez‐Bougie, Marie‐Claire Devilder, Philippe Moreau, Cyrille Touzeau, Agnès Moreau‐Aubry, David Chiron, Catherine Pellat‐Deceunynck
Publikováno v:
HemaSphere, Vol 8, Iss 10, Pp n/a-n/a (2024)
Abstract In multiple myeloma, as in B‐cell malignancies, mono‐ and especially bi‐allelic TP53 gene inactivation is a high‐risk factor for treatment resistance, and there are currently no therapies specifically targeting p53 deficiency. In thi
Externí odkaz:
https://doaj.org/article/13eb39e4b90348b0a8b866dcf7917e42
Autor:
Romane Durand, Céline Bellanger, Charlotte Kervoëlen, Benoit Tessoulin, Christelle Dousset, Emmanuelle Menoret, Hélène Asnagli, Andrew Parker, Philip Beer, Catherine Pellat-Deceunynck, David Chiron
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Innovative therapeutic strategies have emerged over the past decade to improve outcomes for most lymphoma patients. Nevertheless, the aggressive presentation seen in high-risk mantle cell lymphoma (MCL) patients remains an unmet medical need. The hig
Externí odkaz:
https://doaj.org/article/828be1ecc455460bbd0eb5300aac6bcd
Autor:
Ophélie Champion, Alana Soler, Sophie Maïga, Céline Bellanger, Catherine Pellat-Deceunynck, Alexis Talbot, Cyrille Touzeau, Martine Amiot, Patricia Gomez-Bougie
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory multiple myeloma and consequently presenting limited therapeutic options. We analyzed 13 sPCL for their sensitivity to BH
Externí odkaz:
https://doaj.org/article/730d127beed64625af783291e6a9514e
Autor:
Salomé Decombis, Antonin Papin, Céline Bellanger, Clara Sortais, Christelle Dousset, Yannick Le Bris, Thiphanie Riveron, Stéphanie Blandin, Philippe Hulin, Benoit Tessoulin, Mathieu Rouel, Steven Le Gouill, Agnès Moreau-Aubry, Catherine Pellat-Deceunynck, David Chiron
Publikováno v:
Haematologica, Vol 107, Iss 12 (2022)
Aggressive B-cell malignancies, such as mantle cell lymphoma (MCL), are microenvironment-dependent tumors and a better understanding of the dialogs occurring in lymphoma-protective ecosystems will provide new perspectives to increase treatment effici
Externí odkaz:
https://doaj.org/article/7af642ac8ace4558abb9604f51108c87
Autor:
Lina Benaniba, Benoit Tessoulin, Sabrina Trudel, Catherine Pellat-Deceunynck, Martine Amiot, Stéphane Minvielle, Pierre Antoine Gourraud, Sophie de Visme, Hervé Maisonneuve, Anne Lok, Steven Le Gouill, Philippe Moreau, Cyrille Touzeau
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-6 (2019)
Abstract Background Despite recent advances in the treatment of multiple myeloma, the disease constantly relapses and is still considered as incurable. The current knowledge about the biological mechanisms underlying resistance to the different class
Externí odkaz:
https://doaj.org/article/c6cb5f22b85840a19e5d753d26824f3d
Autor:
Benoît Tessoulin, Agnès Moreau-Aubry, Géraldine Descamps, Patricia Gomez-Bougie, Sophie Maïga, Alban Gaignard, David Chiron, Emmanuelle Ménoret, Steven Le Gouill, Philippe Moreau, Martine Amiot, Catherine Pellat-Deceunynck
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-13 (2018)
Abstract Background Human myeloma cell lines (HMCLs) are widely used for their representation of primary myeloma cells because they cover patient diversity, although not fully. Their genetic background is mostly undiscovered, and no comprehensive stu
Externí odkaz:
https://doaj.org/article/5588860c88bf45adab3b11a355d742eb
Autor:
Benoit Tessoulin, Geraldine Descamps, Christelle Dousset, Martine Amiot, Catherine Pellat-Deceunynck
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Prima-1Met (APR-246) was previously shown to be dependent on glutathione inhibition and on ROS induction in cancer cells with mutated or deleted TP53. Because this ROS induction was, at least in part, due to a direct interference with the thioredoxin
Externí odkaz:
https://doaj.org/article/3bacdfcf8c9b4a4e916a25e68db322e7
Autor:
Benoît Tessoulin, Antonin Papin, Patricia Gomez-Bougie, Celine Bellanger, Martine Amiot, Catherine Pellat-Deceunynck, David Chiron
Publikováno v:
Frontiers in Oncology, Vol 8 (2019)
BCL2-family proteins have a central role in the mitochondrial apoptosis machinery and their expression is known to be deregulated in many cancer types. Effort in the development of small molecules that selectively target anti-apoptotic members of thi
Externí odkaz:
https://doaj.org/article/fefe5648e85f44d6bfae86b7c657af3a
Autor:
Laurence Lodé, Audrey Ménard, Laurent Flet, Steven Richebourg, Marion Loirat, Marion Eveillard, Yannick Le Bris, Catherine Godon, Olivier Theisen, Anne-Laure Gagez, Guillaume Cartron, Thérèse Commes-Maerten, Bruno Villemagne, Odile Luycx, Pascal Godmer, Catherine Pellat-Deceunynck, Thierry Soussi, Marie C. Béné, Jacques Delaunay, Pierre Peterlin
Publikováno v:
Haematologica, Vol 103, Iss 4 (2018)
Externí odkaz:
https://doaj.org/article/96b17b029e614598bb8be3cbcb1ec488
Autor:
Pierre-Samuel Gillardin, Géraldine Descamps, Sophie Maiga, Benoit Tessoulin, Hanane Djamai, Benedetta Lucani, David Chiron, Philippe Moreau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck, Agnès Moreau-Aubry
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 1, p 40 (2017)
(1) Background: TP53 deficiency remains a major adverse event in Multiple Myeloma (MM) despite therapeutic progresses. As it is not possible to target TP53 deficiency with pharmacological agents, we explored the possibility of activating another p53
Externí odkaz:
https://doaj.org/article/240adf6af14a47089f9da3ca34c0fd7d